DA4-JC

DA4-JC is a **novel dual agonist** of the glucagon-like peptide 1 receptor (GLP-1 receptor) and the glucose-dependent insulinotropic polypeptide receptor (GIP receptor), engineered with a cell-penetrating sequence to enhance its penetration across the blood-brain barrier. Unlike prior dual agonists modified for longer circulation (e.g., with lipidation), DA4-JC demonstrates *improved brain uptake*, and preclinical studies indicate **superior neuroprotective effects** versus approved GLP-1 analogues such as liraglutide. In the APP/PS1 mouse model of Alzheimer's disease, DA4-JC reversed memory loss, enhanced synaptic plasticity (LTP), reduced amyloid plaque burden, and suppressed neuroinflammation more effectively than liraglutide. The drug acts as a full, balanced agonist at the GLP-1 and GIP receptors, but does not significantly activate the GLP-2 or glucagon receptors. DA4-JC is being investigated primarily for the **treatment of Alzheimer's disease**, with additional potential as a neuroprotective agent in models of Parkinson’s disease.